Abstract
Nanogels have come out as a great potential drug delivery platform due to its prominently high colloidal stability, high drug loading, core-shell structure, good permeation property and can be responsive to environmental stimuli. Such nanoscopic drug carriers have more excellent abilities over conventional nanomaterials for permeating to brain parenchymaand. Nanogel-based system can be nanoengineered to bypass physiological barriers via non-invasive treatment, rendering it a most suitable platform for the management of neurological conditions such as neurodegenerative disorders, brain tumors, epilepsy and ischemic stroke, etc. Therapeutics of central nervous system (CNS) diseases have shown marked limited site-specific delivery of CNS by the poor access of various drugs into the brain, due to the presences of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Hence, the availability of therapeutics delivery strategies is considered as one of the most major challenges facing the treatment of CNS diseases. The primary objective of this review is to elaborate the newer advances of nanogel for CNS drugs delivery, discuss the early preclinical success in the field of nanogel technology and highlight different insights on its potential neurotoxicity.
Overview
- The study focuses on the potential of nanogels as a drug delivery platform for central nervous system (CNS) diseases. The primary objective is to elaborate on the newer advances of nanogel for CNS drugs delivery, discuss early preclinical success, and highlight potential neurotoxicity. The methodology used includes a review of the literature on nanogel-based systems for CNS drug delivery. The study aims to provide insights into the potential of nanogels for CNS drug delivery and their potential impact on the treatment of neurological conditions such as neurodegenerative disorders, brain tumors, epilepsy, and ischemic stroke. The study also highlights the challenges faced in the delivery of therapeutics to the CNS due to the presence of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB).
Comparative Analysis & Findings
- The study compares the outcomes observed under different experimental conditions or interventions detailed in the literature on nanogel-based systems for CNS drug delivery. The study identifies significant differences or similarities in the results between these conditions. The key findings of the study include the ability of nanogels to bypass physiological barriers via non-invasive treatment, making them a suitable platform for the management of neurological conditions such as neurodegenerative disorders, brain tumors, epilepsy, and ischemic stroke. The study also highlights the potential of nanogels for site-specific delivery of CNS drugs, which is limited by the poor access of various drugs into the brain due to the presence of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB).
Implications and Future Directions
- The study's findings highlight the potential of nanogels for CNS drug delivery and their potential impact on the treatment of neurological conditions such as neurodegenerative disorders, brain tumors, epilepsy, and ischemic stroke. The study identifies limitations in the delivery of therapeutics to the CNS due to the presence of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). The study suggests future research directions that could build on the results of the study, explore unresolved questions, or utilize novel approaches. The study also highlights the potential of nanogels for site-specific delivery of CNS drugs, which is limited by the poor access of various drugs into the brain due to the presence of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB).